Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)

Ibn Sina Hospital

Status: Completed

Conditions: Infertility

Treatments: Other: Medium Supplemented with Chaetoglobosin A

Study type: Interventional

Funder types: Other

Identifiers

NCT03678584

IbnSinaIVF-ICSI-CA

Details and patient eligibility

About

Vienna Consensus has identified 10% damage rate after ICSI as a competency value. Despite the highest quality embryologists doing ICSI, degeneration sometimes occurs due to oocyte factors such as the fragile membrane, etc. Chaetoglobosin A serves to facilitate spindle or pronuclear transfer procedures helping to reduce the damage rate with no harm reported. Using Chaetoglobosin A during ICSI could serve to rescue some oocytes from the degeneration allowing for more chances of viable zygotes.

Enrollment: 300 patients

Sex: Female

Ages: 18 to 42 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All ICSI participants agreed

Exclusion criteria

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

300 participants in 2 patient groups

Handling Medium Supplemented with Chaetoglobosin A

Experimental group

Treatment:

Other: Medium Supplemented with Chaetoglobosin A

handling Medium as it is.

No Intervention group